论文部分内容阅读
目的观察三苯氧胺在子宫内膜异位症术后临床应用效果。方法对２３例经病理证实的子宫内膜异位症患者，术后采用三苯氧胺辅助治疗，三苯氧胺１０ｍｇ口服，２次／ｄ，连服３～６个月，同时测定血清ＣＡ１２５作为疗效监测。结果用药后控制症状为１００％，消除残余病灶为９７．８％，血清ＣＡ１２５诊断子宫内膜异位症的阳性率为７６．１％，用药后随着症状和体征的改善，血清ＣＡ１２５明显下降。随访３～１２个月，仅１例复发，复发率为２．１７％，２例合并不孕患者，１例妊娠分娩，三苯氧胺的副作用在停药后迅速消失。结论三苯氧胺是治疗子宫内膜异位症首选药物之一
Objective To observe the clinical effect of tamoxifen after endometriosis. Methods Twenty-three patients with endometriosis confirmed by pathology were treated with adjuvant tamoxifen after oral administration of tamoxifen 10 mg twice daily for 3 to 6 months. Serum CA125 was also measured as a curative effect. Results After treatment, the control symptom was 100% and the residual disease was eliminated by 97.8%. The positive rate of serum CA125 in diagnosing endometriosis was 76.1%. After treatment, the serum CA125 was significantly decreased with the improvement of symptoms and signs . Follow-up ranged from 3 to 12 months. Only 1 case relapsed with a recurrence rate of 2.17%. Two cases of infertile patients and one case of pregnancy and delivery had the side effects of tamoxifen disappearing rapidly after withdrawal. Conclusion Tamoxifen is one of the preferred drugs for the treatment of endometriosis